{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T20:42:49Z","timestamp":1781728969715,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T00:00:00Z","timestamp":1622851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T00:00:00Z","timestamp":1622851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770161"],"award-info":[{"award-number":["81770161"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970140"],"award-info":[{"award-number":["81970140"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s00277-021-04544-6","type":"journal-article","created":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T09:02:52Z","timestamp":1622883772000},"page":"2215-2228","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Adolescents experienced more treatment failure than children with chronic myeloid leukemia receiving imatinib as frontline therapy: a retrospective multicenter study"],"prefix":"10.1007","volume":"100","author":[{"given":"Xuelin","family":"Dou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangyuan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingcheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zesheng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueping","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xielan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sixuan","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxian","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanjun","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhilin","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixia","family":"Di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7131-0522","authenticated-orcid":false,"given":"Qian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,5]]},"reference":[{"issue":"2","key":"4544_CR1","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00277-015-2314-2","volume":"94","author":"M H\u00f6glund","year":"2015","unstructured":"H\u00f6glund M, Sandin F, Simonsson B (2015) Epidemiology of chronic myeloid leukaemia: an update. Ann Hematol 94(2):241\u2013247","journal-title":"Ann Hematol"},{"issue":"6","key":"4544_CR2","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6):872\u2013884","journal-title":"Blood"},{"key":"4544_CR3","unstructured":"Ries LAG SM, Gurney JG, Linet M, Tamra T, Young JL, Bunin GR (eds) (1999) Cancer incidence and survival among children and adolescents: United States SEER Program 1975\u20131995, National Cancer Institute, SEER Program. NIH Pub. No. 99\u20134649. Bethesda, MD"},{"issue":"7","key":"4544_CR4","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.3109\/10428194.2012.745525","volume":"54","author":"Y Chen","year":"2013","unstructured":"Chen Y, Wang H, Kantarjian H et al (2013) Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009. Leuk Lymphoma 54(7):1411\u20131417","journal-title":"Leuk Lymphoma"},{"issue":"22","key":"4544_CR5","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1182\/blood.2018882233","volume":"133","author":"N Hijiya","year":"2019","unstructured":"Hijiya N, Suttorp M (2019) How I treat chronic myeloid leukemia in children and adolescents. Blood 133(22):2374\u20132384","journal-title":"Blood"},{"issue":"9","key":"4544_CR6","doi-asserted-by":"publisher","first-page":"e27827","DOI":"10.1002\/pbc.27827","volume":"66","author":"U Athale","year":"2019","unstructured":"Athale U, Hijiya N, Patterson BC et al (2019) Management of chronic myeloid leukemia in children and adolescents: recommendations from the Children\u2019s Oncology Group CML Working Group. Pediatr Blood Cancer 66(9):e27827","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"4544_CR7","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1182\/blood-2015-06-648667","volume":"127","author":"N Hijiya","year":"2016","unstructured":"Hijiya N, Schultz KR, Metzler M et al (2016) Pediatric chronic myeloid leukemia is a unique disease that requires a different approach. Blood 127(4):392\u2013399","journal-title":"Blood"},{"issue":"1","key":"4544_CR8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/annonc\/mdu490","volume":"26","author":"F Castagnetti","year":"2015","unstructured":"Castagnetti F, Gugliotta G, Baccarani M et al (2015) Differences among young adults, adults and elderly chronic myeloid leukemia patients. Annals of oncology\u202f: official Ann Oncol 26(1):185\u2013192","journal-title":"Annals of oncology : official journal of the European Society for Medical Oncology"},{"issue":"1","key":"4544_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00277-013-1937-4","volume":"93","author":"L Kalmanti","year":"2014","unstructured":"Kalmanti L, Saussele S, Lauseker M et al (2014) Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV. Ann Hematol 93(1):71\u201380","journal-title":"Ann Hematol"},{"issue":"7","key":"4544_CR10","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.3324\/haematol.2011.056721","volume":"97","author":"N Pemmaraju","year":"2012","unstructured":"Pemmaraju N, Kantarjian H, Shan J et al (2012) Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. Haematologica 97(7):1029\u20131035","journal-title":"Haematologica"},{"issue":"15","key":"4544_CR11","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1182\/blood-2014-05-578567","volume":"124","author":"F Millot","year":"2014","unstructured":"Millot F, Guilhot J, Baruchel A et al (2014) Impact of early molecular response in children with chronic myeloid leukemia treated in the French Glivec phase 4 study. Blood 124(15):2408\u20132410","journal-title":"Blood"},{"issue":"3","key":"4544_CR12","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/bjh.13453","volume":"170","author":"F Giona","year":"2015","unstructured":"Giona F, Putti MC, Micalizzi C et al (2015) Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience. Br J Haematol 170(3):398\u2013407","journal-title":"Br J Haematol"},{"issue":"8","key":"4544_CR13","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1007\/s00277-015-2367-2","volume":"94","author":"D Gurrea Salas","year":"2015","unstructured":"Gurrea Salas D, Glauche I, Tauer JT et al (2015) Can prognostic scoring systems for chronic myeloid leukemia as established in adults be applied to pediatric patients? Ann Hematol 94(8):1363\u20131371","journal-title":"Ann Hematol"},{"key":"4544_CR14","volume-title":"Rudolph's Pediatrics, 22e","author":"CE Irwin Jr","year":"2011","unstructured":"Irwin CE Jr (2011) Chapter 63. Somatic Growth and Development. In: Rudolph CD, Rudolph AM, Lister GE et al (eds) Rudolph\u2019s Pediatrics, 22e. The McGraw-Hill Companies, New York"},{"issue":"4","key":"4544_CR15","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.jpeds.2011.03.046","volume":"159","author":"H Shima","year":"2011","unstructured":"Shima H, Tokuyama M, Tanizawa A et al (2011) Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia. J Pediatr 159(4):676\u2013681","journal-title":"J Pediatr"},{"issue":"18","key":"4544_CR16","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.1016\/j.ejca.2014.10.007","volume":"50","author":"F Millot","year":"2014","unstructured":"Millot F, Guilhot J, Baruchel A et al (2014) Growth deceleration in children treated with imatinib for chronic myeloid leukaemia. Eur J Cancer 50(18):3206\u20133211","journal-title":"Eur J Cancer"},{"key":"4544_CR17","doi-asserted-by":"crossref","unstructured":"Qin Y-Z, Jiang Q, Jiang H et al (2013) Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level? Leuk Res\u00a037(9):1035\u20131040","DOI":"10.1016\/j.leukres.2013.06.003"},{"issue":"4","key":"4544_CR18","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT et al (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34(4):966\u2013984","journal-title":"Leukemia"},{"issue":"4","key":"4544_CR19","doi-asserted-by":"publisher","first-page":"798","DOI":"10.3390\/cancers13040798","volume":"13","author":"M Suttorp","year":"2021","unstructured":"Suttorp M, Millot F, Sembill S et al (2021) Definition, epidemiology, pathophysiology, and essential criteria for diagnosis of pediatric chronic myeloid leukemia. Cancers (Basel) 13(4):798","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4544_CR20","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1542\/peds.2004-2473","volume":"116","author":"F Millot","year":"2005","unstructured":"Millot F, Traore P, Guilhot J et al (2005) Clinical and Biological Features at Diagnosis in 40 Children With Chronic Myeloid Leukemia. Pediatrics 116(1):140\u2013143","journal-title":"Pediatrics"},{"issue":"11","key":"4544_CR21","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1002\/gcc.21989","volume":"51","author":"M Krumbholz","year":"2012","unstructured":"Krumbholz M, Karl M, Tauer JT et al (2012) Genomic BCR-ABL1 breakpoints in pediatric chronic myeloid leukemia. Genes Chromosom Cancer 51(11):1045\u20131053","journal-title":"Genes Chromosom Cancer"},{"issue":"5","key":"4544_CR22","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/s41375-018-0341-4","volume":"33","author":"M Baccarani","year":"2019","unstructured":"Baccarani M, Castagnetti F, Gugliotta G et al (2019) The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia An international overview. Leukemia 33(5):1173\u20131183","journal-title":"Leukemia"},{"key":"4544_CR23","doi-asserted-by":"crossref","unstructured":"Sembill S, G\u00f6hring G, Schirmer E, Lutterloh F, Suttorp M, Metzler M, Karow A (2021) Paediatric chronic myeloid leukaemia presenting in de novo or secondary blast phase - a comparison of clinical and genetic characteristics. Br J Haematol. 193(3):613-618","DOI":"10.1111\/bjh.17378"},{"issue":"10","key":"4544_CR24","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.3324\/haematol.2017.170035","volume":"102","author":"F Millot","year":"2017","unstructured":"Millot F, Guilhot J, Suttorp M et al (2017) Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents. Haematologica 102(10):1704\u20131708","journal-title":"Haematologica"},{"issue":"7","key":"4544_CR25","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1038\/s41375-018-0179-9","volume":"32","author":"M Suttorp","year":"2018","unstructured":"Suttorp M, Schulze P, Glauche I et al (2018) Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial. Leukemia 32(7):1657\u20131669","journal-title":"Leukemia"},{"issue":"6","key":"4544_CR26","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.1111\/bjh.16388","volume":"188","author":"F Giona","year":"2020","unstructured":"Giona F, Malaspina F, Putti MC et al (2020) Results and outcome of intermittent imatinib (ON\/OFF schedule) in children and adolescents with chronic myeloid leukaemia. Br J Haematol 188(6):e101\u2013e105","journal-title":"Br J Haematol"},{"issue":"20","key":"4544_CR27","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1200\/JCO.2010.32.7114","volume":"29","author":"F Millot","year":"2011","unstructured":"Millot F, Baruchel A, Guilhot J et al (2011) Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial. J Clin Oncol 29(20):2827\u20132832","journal-title":"J Clin Oncol"},{"issue":"4","key":"4544_CR28","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1111\/bjh.15826","volume":"185","author":"CMA de Bruijn","year":"2019","unstructured":"de Bruijn CMA, Millot F, Suttorp M et al (2019) Discontinuation of imatinib in children with chronic myeloid leukaemia in sustained deep molecular remission: results of the STOP IMAPED study. Br J Haematol 185(4):718\u2013724","journal-title":"Br J Haematol"},{"issue":"1","key":"4544_CR29","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/pbc.23031","volume":"57","author":"MA Champagne","year":"2011","unstructured":"Champagne MA, Fu CH, Chang M et al (2011) Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children\u2019s Oncology Group. Pediatr Blood Cancer 57(1):56\u201362","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"4544_CR30","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/bjh.16338","volume":"189","author":"J Rossoff","year":"2020","unstructured":"Rossoff J, Huynh V, Rau RE et al (2020) Experience with ponatinib in paediatric patients with leukaemia. Br J Haematol 189(2):363\u2013368","journal-title":"Br J Haematol"},{"issue":"13","key":"4544_CR31","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1200\/JCO.2017.75.9597","volume":"36","author":"L Gore","year":"2018","unstructured":"Gore L, Kearns PR, de Martino ML et al (2018) Dasatinib in pediatric patients with chronic myeloid leukemia in chronic phase: results from a phase II trial. J Clin Oncol 36(13):1330\u20131338","journal-title":"J Clin Oncol"},{"key":"4544_CR32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejca.2019.03.020","volume":"115","author":"F Millot","year":"2019","unstructured":"Millot F, Maledon N, Guilhot J et al (2019) Favourable outcome of de novo advanced phases of childhood chronic myeloid leukaemia. Eur J Cancer 115:17\u201323","journal-title":"Eur J Cancer"},{"key":"4544_CR33","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s12185-020-03042-1","volume":"113","author":"Y Cai","year":"2021","unstructured":"Cai Y, Liu C, Guo Y et al (2021) Long-term safety and efficacy of imatinib in pediatric patients with chronic myeloid leukemia: single-center experience from China. Int J Hematol 113:413\u2013421","journal-title":"Int J Hematol"},{"issue":"2","key":"4544_CR34","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/pbc.24521","volume":"61","author":"F Millot","year":"2014","unstructured":"Millot F, Claviez A, Leverger G et al (2014) Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase. Pediatr Blood Cancer 61(2):355\u2013357","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"4544_CR35","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1093\/jpepsy\/jsw039","volume":"42","author":"JM Rohan","year":"2017","unstructured":"Rohan JM, Fukuda T, Alderfer MA et al (2017) Measuring medication adherence in pediatric cancer: an approach to validation. J Pediatr Psychol 42(2):232\u2013244","journal-title":"J Pediatr Psychol"},{"issue":"1","key":"4544_CR36","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1182\/asheducation-2010.1.368","volume":"2010","author":"M Suttorp","year":"2010","unstructured":"Suttorp M, Millot F (2010) Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stem-cell transplantation. Hematology 2010(1):368\u2013376","journal-title":"Hematology"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04544-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-021-04544-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04544-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T00:42:57Z","timestamp":1672360977000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-021-04544-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,5]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["4544"],"URL":"https:\/\/doi.org\/10.1007\/s00277-021-04544-6","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,5]]},"assertion":[{"value":"17 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}